Direct to employer Wegovy comes to Andel as CenterWell Pharmacy joins

Andel, a company that lets employers pay for medicines outside their health plans, said on October 28 that it will offer direct to employer Wegovy through a deal with Novo. The same day it named CenterWell Pharmacy as a dispensing and home delivery partner for new drug lines beyond GLP 1s, starting with immunology. Neither release gives a price for workers or employers. This story sets out what was announced, how the money is meant to flow, and what remains unclear for patients, pharmacies and the companies that pay.

What Andel announced on October 28

In the first release, Andel said a collaboration with Novo will bring Wegovy to its employer network. The company listed three forms: the Wegovy injection, the once daily Wegovy pill and Wegovy HD, and said the pill and HD both launched earlier in 2026. Andel calls itself a cooperative marketplace that links employers with drug makers, and it says its app handles each step from checking a prescription to delivery. Tom Scales, a senior vice president for market access and public affairs at Novo, said the partnership "creates another way for employers to support that step" toward treatment. The release does not say how many employers or workers use Andel today, or which states it serves.

The second release covered a pharmacy deal. Andel said CenterWell Pharmacy will dispense and deliver eligible prescriptions for its new business lines, naming immunology first and leaving the rest open. Founder and chief executive Jay Bregman framed the move as a step past weight loss drugs. "GLP-1s were the starting point," he said, adding that CenterWell gives Andel the pharmacy capabilities to take its model into immunology and other areas. Andel also says it runs its own licensed pharmacy, Andel Pharmacy LLC. The releases do not say whether Wegovy prescriptions will be filled there, by CenterWell, or by both, which matters to anyone tracking where a box ships from and who answers questions about it.

How the employer money is meant to flow

Andel's pitch for direct to employer Wegovy is control over the bill. Under the Novo release, each employer picks how much it will put toward a worker's treatment, which lowers what the worker pays out of pocket. Andel says it works next to existing benefits, lets members keep their own doctors and passes along pricing set directly by the manufacturer. The company also says it runs on tax free dollars rather than insurance, a claim neither release explains in detail. For a worker, that means the monthly cost depends on two numbers that Andel has not published: the price it gets from Novo and the share an employer chooses to cover. Those two figures will decide whether this route beats other options.

For a worker, that means the monthly cost depends on two numbers that Andel has not published: the price it gets from Novo and the share an employer chooses to cover.

The fine print matters here. Andel's own disclaimer says its drug program is not insurance, that members pay the reduced charges themselves, and that the program does not pay providers on their behalf. Lower prices apply only at providers that have signed on to its network and can vary by provider. That differs from a plan benefit, where an insurer or pharmacy benefit manager pays the pharmacy and the spend usually counts toward a deductible. Readers weighing routes can use our guide to the four prices of one pen, since Andel sits somewhere between a cash price and a copay. Whether payments made through Andel count toward a worker's deductible or yearly out of pocket limit is not addressed in either release.

Why employer GLP 1 coverage is under strain

The deal lands as many companies pull back on weight loss drugs. A WTW survey we reported found that 53% of larger employers cover GLP 1 drugs for weight loss, down from 57%, as 2027 costs climb. A separate five year study we covered found that other medical spending rose about 22 cents for every dollar spent on the drugs, which weakens the case that they pay for themselves. Andel is betting that firms dropping employer GLP 1 coverage may still fund a fixed amount they set themselves, and direct to employer Wegovy is its first test of that idea. That is a business plan, not a result, and neither release offers data on uptake or savings.

Andel used a second set of figures to explain its move beyond GLP 1s. Citing IQVIA, it said US specialty drug spending rose by $27 billion in 2024, driven largely by cancer and immunology medicines, and that use of immunology drugs grew 72% from 2019 to 2024. Citing a 2025 Navitus report on commercial pharmacy benefits, it said targeted immunomodulators were the costliest specialty group at more than $22 per member per month, nearly twice cancer drug spending. These numbers come from the release, and we could not open the IQVIA page through its link. They help explain why employers worry about immunology drug costs, but they say nothing about what Andel will charge for any of those medicines.

What workers and pharmacies still do not know

Several basic questions about direct to employer Wegovy remain open. Neither release names a single employer client, lists a monthly price for any Wegovy form, or says when the Novo offer or the CenterWell service goes live. It is also unclear which immunology drugs are in scope, which drug makers have signed on besides Novo, and whether Andel can reach workers in every state. A prescriber still decides who qualifies for Wegovy, and Scales said the partnership aims to help eligible people get treatment "in consultation with their healthcare professional." For prescribers, the usual clinical checks and paperwork still apply even when an employer, not an insurer, pays part of the bill.

For retail and specialty pharmacies, routes like this one move some fills away from the plan benefit and toward home delivery by a chosen partner. The trend is not new: a USC and RAND preprint we covered estimated that about 9 million US adults got GLP 1 drugs through routes outside insurance, such as online prescribers, med spas, compounding or foreign pharmacies. Andel's model differs from compounded copies because it supplies the branded drug through licensed pharmacies with the maker's backing. Even so, a worker should confirm what is dispensed, who fills it and what the full yearly cost will be before leaving a plan benefit or a cash program. This article is for information only and is not medical or financial advice.

Conclusion

Direct to employer Wegovy through Andel gives some companies a new way to fund obesity treatment without adding it to their health plan, and the CenterWell deal shows Andel wants the same role for immunology drugs. What it does not yet give readers is a price, a start date or any proof of savings. Until Andel or its partners publish those numbers, workers and employers should treat the offer as one more route to compare against plan coverage, Medicare programs and manufacturer cash prices.